Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966099 | 0.89 | KDM4E (0.44) | KDM4EMAPTALDH1A1SMN1; SMN2FEN1 | |
| SCHEMBL1966018 | 0.87 | LMNA (0.49) | KDM4EMAPTALDH1A1SMN1; SMN2FEN1 | |
| SCHEMBL1966103 | 0.85 | KMT2A (0.50) | KDM4EMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1967350 | 0.85 | KDM4E (0.54) | KDM4EMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1965910 | 0.82 | ALDH1A1 (0.47) | KDM4EMAPTALDH1A1FEN1KMT2A | |
| SCHEMBL1968371 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2FEN1KMT2A | |
| SCHEMBL1967127 | 0.81 | KDM4E (0.48) | KDM4EMAPTALDH1A1FEN1KMT2A | |
| SCHEMBL1965742 | 0.80 | KDM4E (0.47) | KDM4EMAPTALDH1A1SMN1; SMN2ATM | |
| SCHEMBL1973864 | 0.80 | FEN1 (0.44) | KDM4EPTGER3MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1966325 | 0.80 | EGLN1 (0.49) | KDM4EPTGER3ALDH1A1SMN1; SMN2FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | KDM4E 471/4885PTGER3 3237/4885MAPT 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.